Publications of Véronique BAART
Bookmark and Share    
Full Text
See detailClinical outcomes of 130 patients with primary and secondary lung tumors treated with Cyberknife robotic stereotactic body radiotherapy
Janvary, Zsolt Levente; JANSEN, Nicolas ULiege; BAART, Véronique ULiege et al

in Radiology and Oncology (2017), 51(2), 178-186

Background: Authors report clinical outcomes of patients treated with robotic stereotactic body radiotherapy (SBRT) for primary, recurrent and metastatic lung lesions. Patients and methods: 130 patients ... [more ▼]

Background: Authors report clinical outcomes of patients treated with robotic stereotactic body radiotherapy (SBRT) for primary, recurrent and metastatic lung lesions. Patients and methods: 130 patients with 160 lesions were treated with Cyberknife SBRT, including T1-3 primary lung cancers (54%), recurrent tumors (22%) and pulmonary metastases (24%). The mean biologically equivalent dose (BED10Gy) was 151 Gy (72–180 Gy). Median prescribed dose for peripheral and central lesions was 3x20 Gy and 3x15 Gy, respectively. Local control (LC), overall survival (OS), and cause-specific survival (CSS) rates, early and late toxicities are reported. Statistical analysis was performed to identify factors influencing local tumor control. Results: Median follow-up time was 21 months. In univariate analysis, higher dose was associated with better LC and a cut-off value was detected at BED10Gy ≤ 112.5 Gy, resulting in 1-, 2-, and 3-year actuarial LC rates of 93%, vs 73%, 80% vs 61%, and 63% vs 54%, for the high and low dose groups, respectively (p = 0.0061, HR = 0.384). In multivariate analysis, metastatic origin, histological confirmation and larger Planning Target Volume (PTV) were associated with higher risk of local failure. Actuarial OS and CSS rates at 1, 2, and 3 years were 85%, 74% and 62%, and 93%, 89% and 80%, respectively. Acute and late toxicities ≥ Gr 3 were observed in 3 (2%) and 6 patients (5%), respectively. Conclusions: Our favorable LC and survival rates after robotic SBRT, with low rates of severe toxicities, are coherent with the literature data in this mixed, non-selected study population. [less ▲]

Detailed reference viewed: 53 (6 ULiège)
Full Text
See detailAi-je bien entendu ? Je peux me faire traiter autrement que par chirurgie pour mon schwannome de l’acoustique
COUCKE, Philippe ULiege; JANVARY, Zsolt Levente ULiege; BAART, Véronique ULiege et al

in Revue Médicale de Liège (2011), 66(10), 521-528

L’histoire du schwannome du nerf acoustique (SV) montre un déplacement du «standard de traitement» de la microchirurgie vers la radiothérapie. Pour ce type de tumeurs bénignes, le traitement a pour but ... [more ▼]

L’histoire du schwannome du nerf acoustique (SV) montre un déplacement du «standard de traitement» de la microchirurgie vers la radiothérapie. Pour ce type de tumeurs bénignes, le traitement a pour but d’éviter les complications fonctionnelles et de préserver la capacité auditive. Après microchirurgie pour une lésion de moins de 25 mm, on observera que le nerf facial est indemne dans approximativement 60% des cas et que la fonctionnalité du VIII est préservée dans 15% des cas pour des SV de plus de 15 mm et, dans 50% des cas, pour des SV de moins de 15 mm. Les différents progrès techniques et informatiques dans le domaine de la radiothérapie permettent aujourd’hui d’obtenir un taux de contrôle tumoral variant de 92 à 98% avec une morbidité quasi inexistante au niveau du nerf facial (<2%). La capacité auditive est maintenue dans approximativement 70% des cas. Forts de ces chiffres, on peut estimer que la prise en charge de ce type de tumeurs bénignes doit se faire par radiothérapie. [less ▲]

Detailed reference viewed: 166 (22 ULiège)
See detailPET/CT imaging of skull base meningiomas using 1-18F-fluoro-L-tyrosine; initial report.
RUTTEN, I.; CABAY, Jean-Evrard ULiege; WITHOFS, Nadia ULiege et al

in PROCEEDINGS OF XIIIth SYMPOSIUM OF THE BELGIAN SOCIETY OF NUCLEAR MEDICINE (2007, May)

Detailed reference viewed: 14 (0 ULiège)
Full Text
See detailPET/CT of skull base meningiomas using 2-F-18-fluoro-L-tyrosine: Initial report
Rutten, Isabelle; Cabay, Jean-Evrard ULiege; Withofs, Nadia ULiege et al

in Journal of Nuclear Medicine (2007), 48(5), 720-725

Precise delineation of the shape of skull base meningiomas is critical for their treatment and follow-up but is often difficult using conventional imaging such as CT and MRI. We report our results with ... [more ▼]

Precise delineation of the shape of skull base meningiomas is critical for their treatment and follow-up but is often difficult using conventional imaging such as CT and MRI. We report our results with PET/CT and 2-(18)F-fluoro-L-tyrosine ((18)F-TYR), a marker of amino acid transport, as part of the yearly follow-up of irradiated patients. METHODS: Eleven patients (mean age, 56.5 y) with skull base meningiomas (n=13 lesions) previously irradiated were included. All patients received 300 MBq of (18)F-TYR and were imaged after 30 min of uptake, using a dedicated PET/CT system. The images were first visually examined, and regions of interest (ROI) were then placed over the transaxial PET slice showing the highest uptake. Another ROI was placed over the normal parietal cortex. Tumor-to-cortex activity ratios were obtained by dividing the maximum pixel value in the tumor ROI by the maximum pixel value in the cortex ROI. The PET/CT images were compared with the MR images obtained as part of routine follow-up. RESULTS: Accumulation of the tracer was higher in all meningiomas than in the surrounding tissue. The tumor-to-cortex activity ratio was 2.53 +/- 0.35 (range, 1.3-6). Nonneoplastic tissue such as hyperemic cavernous sinus did not take up the radionuclide and was therefore easily distinguished from the meningioma. The (18)F-TYR anomalies completely overlapped with the MR image in 54% of the tumors, extended beyond the MRI lesion in 38% of the tumors, and were smaller in 8% of the tumors. CONCLUSION: Meningiomas of the skull base are clearly visualized using (18)F-TYR PET/CT, even after irradiation. In addition to MRI, (18)F-TYR PET/CT images may contribute to the evaluation, delineation, and follow-up of these tumors. [less ▲]

Detailed reference viewed: 88 (11 ULiège)
Full Text
See detailPET/CT imaging of skull base meningiomas using 2-18F-fluoro-L-tyrosine : Initial report.
Rutten, Isabelle; Cabay, Jean-Evrard ULiege; Withofs, Nadia ULiege et al

in Journal of Nuclear Medicine (2007), 48(SUPPL), 11

Detailed reference viewed: 17 (5 ULiège)